-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Industry News] In recent years, with the continuous improvement of the medical market, medical companies have embarked on the road to listing, and set off a "listing tide"
.
At present, the time has come to 2022, and many medical companies are still accelerating their listing in order to usher in more development opportunities
.
A few days ago, Tianyi Medical issued an announcement that with the approval of the Shenzhen Stock Exchange, the RMB ordinary shares issued by the company will be listed on the Shenzhen Stock Exchange Growth Enterprise Market on April 7, 2022.
The number of shares issued this time: 14,736,842 shares
.
Coincidentally, on April 2, Shanghai MicroPort Electrophysiology Technology Co.
, Ltd.
"submitted for registration" for the IPO on the Science and Technology Innovation Board
.
It is reported that on March 31, the Shanghai Stock Exchange Science and Technology Innovation Board Listing Committee held the 24th review meeting in 2022.
According to the review results of the meeting, the MicroPort Electrophysiology Science and Technology Innovation Board has been approved for the first time
.
According to the data, Electrophysiology is a high-tech enterprise focusing on the R&D, production and sales of innovative medical devices in the field of electrophysiological interventional diagnosis and ablation therapy
.
The smooth passing of this electrophysiology meeting indicates that the domestic innovative medical device industry will usher in new development opportunities
.
In addition, on February 28, according to the disclosure of the Hong Kong Stock Exchange, Zhiyun Health Technology Group once again submitted a listing application to the main board of the Hong Kong Stock Exchange, with Morgan Stanley and JPMorgan Chase as the joint sponsors
.
As far as the author understands, in fact, on August 27, 2021, Zhiyun Health had already submitted a listing application form to the Hong Kong Stock Exchange
.
The industry believes that many medical companies have begun to promote the pace of listing, mainly to obtain strong capital support to promote the company's continuous development
.
It is reported that in recent years, with the support of a series of favorable national policies and the increase in per capita medical expenditure, China's medical industry has actually entered a stage of rapid development
.
According to data, as of March 28, there were a total of 77 listed companies with A shares belonging to the Dongcai industry in the medical device category, of which 56 have disclosed their annual performance in 2021
.
From the perspective of net profit attributable to shareholders of the parent company, 51 listed medical device companies have achieved profits, accounting for as high as 91%
.
Under the circumstance that the general environment is improving and the performance continues to grow, it is not surprising that a large number of companies choose to go public in order to obtain more development opportunities
.
It is worth mentioning that due to the faster listing speed of Hong Kong stocks, many companies have also chosen to list in Hong Kong
.
It is understood that since the Hong Kong Stock Exchange revised the "Listing Rules" in 2018 to introduce Chapter 18A, allowing unprofitable biotech companies to list in Hong Kong, China, there has been a continuous upsurge in medical companies listing in Hong Kong
.
According to data, as of December 17, 2021, a total of 92 new stocks have been listed, and the initial public fundraising amounted to 318.
9 billion yuan
.
However, it should be noted that under the background of the current medical companies getting together and listing, many medical companies have also failed to go public
.
From February 14th to 21st this year, three medical companies were listed due to the expiration of their prospectus
.
In this regard, the industry suggests that companies should increase their grasp of the expiration of the prospectus, so as not to interrupt their own listing process
.
In addition, we must always pay attention to changes and new developments in the listing policy and respond in a timely manner
.
Disclaimer: Under no circumstances shall the information or opinions expressed in this article constitute investment advice to anyone
.
.
At present, the time has come to 2022, and many medical companies are still accelerating their listing in order to usher in more development opportunities
.
A few days ago, Tianyi Medical issued an announcement that with the approval of the Shenzhen Stock Exchange, the RMB ordinary shares issued by the company will be listed on the Shenzhen Stock Exchange Growth Enterprise Market on April 7, 2022.
The number of shares issued this time: 14,736,842 shares
.
Coincidentally, on April 2, Shanghai MicroPort Electrophysiology Technology Co.
, Ltd.
"submitted for registration" for the IPO on the Science and Technology Innovation Board
.
It is reported that on March 31, the Shanghai Stock Exchange Science and Technology Innovation Board Listing Committee held the 24th review meeting in 2022.
According to the review results of the meeting, the MicroPort Electrophysiology Science and Technology Innovation Board has been approved for the first time
.
According to the data, Electrophysiology is a high-tech enterprise focusing on the R&D, production and sales of innovative medical devices in the field of electrophysiological interventional diagnosis and ablation therapy
.
The smooth passing of this electrophysiology meeting indicates that the domestic innovative medical device industry will usher in new development opportunities
.
In addition, on February 28, according to the disclosure of the Hong Kong Stock Exchange, Zhiyun Health Technology Group once again submitted a listing application to the main board of the Hong Kong Stock Exchange, with Morgan Stanley and JPMorgan Chase as the joint sponsors
.
As far as the author understands, in fact, on August 27, 2021, Zhiyun Health had already submitted a listing application form to the Hong Kong Stock Exchange
.
The industry believes that many medical companies have begun to promote the pace of listing, mainly to obtain strong capital support to promote the company's continuous development
.
It is reported that in recent years, with the support of a series of favorable national policies and the increase in per capita medical expenditure, China's medical industry has actually entered a stage of rapid development
.
According to data, as of March 28, there were a total of 77 listed companies with A shares belonging to the Dongcai industry in the medical device category, of which 56 have disclosed their annual performance in 2021
.
From the perspective of net profit attributable to shareholders of the parent company, 51 listed medical device companies have achieved profits, accounting for as high as 91%
.
Under the circumstance that the general environment is improving and the performance continues to grow, it is not surprising that a large number of companies choose to go public in order to obtain more development opportunities
.
It is worth mentioning that due to the faster listing speed of Hong Kong stocks, many companies have also chosen to list in Hong Kong
.
It is understood that since the Hong Kong Stock Exchange revised the "Listing Rules" in 2018 to introduce Chapter 18A, allowing unprofitable biotech companies to list in Hong Kong, China, there has been a continuous upsurge in medical companies listing in Hong Kong
.
According to data, as of December 17, 2021, a total of 92 new stocks have been listed, and the initial public fundraising amounted to 318.
9 billion yuan
.
However, it should be noted that under the background of the current medical companies getting together and listing, many medical companies have also failed to go public
.
From February 14th to 21st this year, three medical companies were listed due to the expiration of their prospectus
.
In this regard, the industry suggests that companies should increase their grasp of the expiration of the prospectus, so as not to interrupt their own listing process
.
In addition, we must always pay attention to changes and new developments in the listing policy and respond in a timely manner
.
Disclaimer: Under no circumstances shall the information or opinions expressed in this article constitute investment advice to anyone
.
